RCAG
HRTX icon

Rehmann Capital Advisory Group’s Heron Therapeutics HRTX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-32
Closed -$1.24K – 2162
2018
Q2 		$1.24K Buy
+32
New +$1.02K ﹤0.01% 1917

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Rehmann Capital Advisory Group's HRTX Position: Q3 2018 in Review

Rehmann Capital Advisory Group sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 32 shares — an estimated $1.24K sold.

Rehmann Capital Advisory Group first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $1.24K in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

  • Rehmann Capital Advisory Group reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 32 Heron Therapeutics shares in Q3 2018, an estimated $1.24K.
  • Rehmann Capital Advisory Group first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Heron Therapeutics position peaked at $1.24K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2018, filed 20 Nov 2018.